Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XNCR vs RARE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
XNCR Captures Overall Composite Edge (29.6 SELL vs 43.8 HOLD), While RARE Leads 4–2 on Growth & Valuation Pillars
XNCR Overall Winner
6-Pillar Tally: XNCR 2 – 4 RARE
Matrix Metrics: XNCR 6 – 4 RARE
As of Nov 16, 2026, Xencor, Inc. (XNCR) captures the overall head-to-head institutional edge over Ultragenyx Pharmaceutical Inc. (RARE) on higher Unified Composite conviction (29.6/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while RARE wins 4–2 across the 6-pillar growth and valuation breakdown. XNCR trades at $35.61 (68.0x Forward P/E, -72.7% operating margin) versus RARE at $15.96 (11.2x Forward P/E, -59.9% operating margin).
- Composite vs. Pillar Nuance: While RARE currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -59.9% operating margin) and revenue trajectory (+454.9% vs. +8.1% YoY).
- Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile RARE is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About XNCR vs RARE
XNCR
Head-to-Head Winner
Xencor, Inc.
$35.61
-3.99% 1D
Market Cap
$2.9B
TTM Revenue
$200M
Forward P/E
68.0x
Beta / 30D Vol
1.21β · 87% Vol
Unified Composite Score
29.6
SELL
Tech 50.0
Fund 32.0
Flow 66.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
RARE
Ultragenyx Pharmaceutical Inc.
$15.96
-0.78% 1D
Market Cap
$1.7B
TTM Revenue
$730M
Forward P/E
11.2x
Beta / 30D Vol
1.40β · 57% Vol
Unified Composite Score
43.8
HOLD
Tech 36.0
Fund 53.0
Flow 68.0
Mom 56.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (XNCR 2 – 4 RARE)
1. Valuation Multiples
RARE
Forward P/E
68.0x
11.2x
Trailing P/E
68.0x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
14.8x
2.3x
2. Growth & Scale
XNCR
Revenue Growth (YoY)
+454.9%
+8.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$200M
$730M
Market Cap
$2.9B
$1.7B
3. Profitability & Quality
RARE
Gross Margin
-42.5%
-10.7%
Operating Margin
-72.7%
-59.9%
Net Profit Margin
-58.8%
-71.8%
Return on Equity (ROE)
-19.9%
-608.5%
4. Balance Sheet & Cash Flow
RARE
Cash Generation (TTM)
-$176M
-$447M
Cash Flow Margin
-88.0%
-61.2%
Net Cash / Leverage
$101M Net Debt (0.29x D/E)
-608.5% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
XNCR
Options Structure Phase
BREAKOUT
BREAKDOWN
Current IV / %ile
79.0% (10th %ile)
171.9% (38th %ile)
Put/Call OI Skew
N/A
0.40x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Markup
DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat
RARE
OpEx & R&D Intensity
30.2% of Rev ($61M)
49.2% of Rev ($359M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: XNCR (6) vs RARE (4)| Institutional Metric | XNCR | RARE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.9B | $1.7B | XNCR | |
| Trailing P/E Ratio | 68.0x | N/M | XNCR | |
| Forward P/E Ratio | 68.0x | 11.2x | RARE | |
| Revenue Growth (YoY) | +454.9% | +8.1% | XNCR | |
| Operating Margin (TTM) | -72.7% | -59.9% | RARE | |
| Net Profit Margin | -58.8% | -71.8% | XNCR | |
| Return on Equity (ROE) | -19.9% | -608.5% | XNCR | |
| 52-Week Range Position | 84% ($10–$41) | 12% ($13–$40) | XNCR | |
| Beta / 30D Volatility | 1.21β · 87% Vol | 1.40β · 57% Vol | RARE | |
| Unified Institutional Score | 29.6 / 100 (SELL) | 43.8 / 100 (HOLD) | RARE | |
| Trailing 12M Revenue (USD) | $200M | $730M | Scale | |
| Gross Profit Margin (TTM) | -42.5% | -10.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 14.8x EV/Rev | N/M PEG · 2.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$176M ($101M Net Debt (0.29x D/E)) | -$447M (-608.5% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
XNCR +46.11 pp
3M Horizon
XNCR +77.55 pp
6M Horizon
XNCR +256.01 pp
1Y Horizon
XNCR +206.04 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | XNCR Revenue | RARE Revenue | XNCR Op. Margin | RARE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $40M | $50M | -195.5% | -721.2% | XNCR |
| FY2019 | $160M | $100M | 8.8% | -409.0% | XNCR |
| FY2020 | $120M | $270M | -62.6% | -121.8% | XNCR |
| FY2021 | $280M | $350M | 15.9% | -108.6% | XNCR |
| FY2022 | $160M | $360M | -50.1% | -178.6% | XNCR |
| FY2023 | $170M | $430M | -75.8% | -131.1% | XNCR |
| FY2024 | $110M | $560M | -161.5% | -95.7% | RARE |
| FY2025 | $130M | $670M | -141.4% | -79.5% | RARE |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
XNCR
BREAKOUT
Current IV
79.0%
IV Percentile
10th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
RARE
BREAKDOWN
Current IV
171.9%
IV Percentile
38th %ile
Put/Call OI Skew
0.40x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact RARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
XNCR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
30.2% of Rev ($61M)
90D Engineering Disclosures
0 Published
RARE Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
49.2% of Rev ($359M)
90D Engineering Disclosures
0 Published
Investor FAQ XNCR vs RARE Key Questions & Quantitative Answers
As of Nov 16, 2026, Xencor, Inc. (XNCR) captures the overall head-to-head institutional edge over Ultragenyx Pharmaceutical Inc. (RARE) on higher Unified Composite conviction (29.6/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while RARE wins 4–2 across the 6-pillar growth and valuation breakdown. XNCR trades at $35.61 (68.0x Forward P/E, -72.7% operating margin) versus RARE at $15.96 (11.2x Forward P/E, -59.9% operating margin). Composite vs. Pillar Nuance: While RARE currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -59.9% operating margin) and revenue trajectory (+454.9% vs. +8.1% YoY). Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile RARE is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with RARE at +8.1% YoY revenue growth and +0.0% YoY earnings growth on $730M TTM revenue (-10.7% gross margin, -59.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), XNCR cumulative revenue shifted +225.0% while RARE shifted +1240.0%. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus 49.2% of Rev ($359M) (0 disclosures) for RARE.
RARE screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin), whereas RARE trades at 11.2x Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-61.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus RARE (-608.5% ROE) capital efficiency.
In options market volatility and institutional positioning, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk). By comparison, RARE carries 171.9% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.40x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 57% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
RARE vs XNCR · Reverse Pair
XNCR vs ENTA
· Sector Peer
XNCR vs ANAB
· Sector Peer
XNCR vs RGNX
· Sector Peer
RARE vs PTCT
· Sector Peer
RARE vs AGIO
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem